

NON-ANIMAL APPROACHES FOR COSMETIC SAFETY ASSESSMENT

JAYA VETHAMANICKAM
MECHANISTIC SAFETY SCIENTIST

SAFETY & ENVIRONMENTAL ASSURANCE CENTRE,
UNILEVER, UK



COSMETIC SAFETY - INDIA



- Animal testing ban in cosmetics across the world
- BIS updating the Methods of Test for Safety Evaluation of Cosmetics (IS: 4011)



भारतीय मानक ब्यूरो
BUREAU OF INDIAN STANDARDS
मानक भवन, 9 बहादुरशाह ज़फर मार्ग, नई दिल्ली-110002
MANAK BHAVAN, 9 BAHADUR SHAH ZAFAR MARG
NEW DELHI-110002
www.bis.org.in www.standardsbis.in

IS 4011 : 2018

Indian Standard
METHODS OF TEST FOR
SAFETY EVALUATION OF COSMETICS

ANNEX B

[Table 1, Sl No. (iii)]

ALTERNATE METHODS FOR SAFETY TESTING

(Source Reference — OECD Guidelines, EURL ECVAM Recommendations)

CAN WE USE A NEW INGREDIENT SAFELY?



Can we safely use $x\%$ of an ingredient y
in a product z ?




EU SCIENTIFIC COMMITTEE ON CONSUMER SAFETY (SCCS)




3-4.4	Acute toxicity	39
3-4.4.1	Acute oral toxicity	39
3-4.4.2	Acute dermal toxicity	40
3-4.4.3	Acute inhalation toxicity	40
3-4.5	Skin corrosion and skin irritation	40
3-4.5.1	Skin corrosion.....	40
3-4.5.2	skin irritation.....	41
3-4.6	Serious eye damage and eye irritation	42
3-4.7	Skin sensitisation	44
3-4.8	Repeated dose toxicity	47
3-4.9	Reproductive toxicity.....	48
3-4.10	Mutagenicity / Genotoxicity.....	49
3-4.11	Carcinogenicity	54
3-4.12	Photo-induced toxicity	56
3-4.12.1	Photo-irritation and photo-sensitisation	56
3-4.12.2	Photo-mutagenicity / Photo-genotoxicity.....	57
3-4.13	human data in hazard assessment	58

OECD TESTS THAT DON'T USE ANIMALS: USED FOR MANY END-POINTS




OECD TG437

Eye Irritation




OECD TG430/431
OECD TG439

Skin Corrosion/Irritation



Phototoxicity

OECD TG487




OECD TG471

Genotoxicity

OECD TG473



OECD TG476



OECD TG428

Skin Penetration


OECD TG442C



OECD TG442D

Skin Sensitisation

OECD TG442E



ICCR NINE PRINCIPLES OF NGRA



4 Main overriding principles:

- The overall goal is a human safety risk assessment
- The assessment is exposure led
- The assessment is hypothesis driven
- The assessment is designed to prevent harm

3 Principles describe how a NGRA should be conducted:

- Following an appropriate appraisal of existing information
- Using a tiered and iterative approach
- Using robust and relevant methods and strategies

Principles for documenting NGRA:

- ## 2
- Sources of uncertainty should be characterized and documented
 - The logic of the approach should be transparent and documented



Computational Toxicology 7 (2018) 20–26



Principles underpinning the use of new methodologies in the risk assessment of cosmetic ingredients

Matthew Dent^a, Renata Teixeira Amoral^b, Pedro Amores Da Silva^b, Jay Ansell^c, Fanny Boisleve^d, Masato Hatao^e, Akhiko Hirose^f, Yutaka Kasai^g, Petra Kern^h, Retihsard Kreilingⁱ, Stanley Milstien^j, Beta Montemayor^k, Julcemara Oliveira^l, Andrea Richarz^m, Rob Taelmanⁿ, Eric Vaillancourt^o, Rajeshwar Verma^p, Nashira Vieira O'Reilly Cabral Posada^q, Craig Weiss^r, Hajime Kojima^s


^a Unilever Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 3LQ, UK
^b APOFFCC - Association of the Cosmetic, Toiletry and Fragrance Industry (AOTFFCC), Av. Paulista, 1333 Consórcio Citicor, São Paulo, SP 01311-000, Brazil
^c US Personal Care Products Council (PCPC), 1620 J. St. NW, Suite 2000, Washington, D.C. 20036, USA
^d Johnson & Johnson Simed Biotech France, Avenue de Magenta, CS 10811, F-75756 Paris 18, 80222 Colas, France
^e Japan Cosmetic Industry Association (JCIA), Mori-City, Kashiwa-ku, 5-5-5, Torrance, Minami-Ku, Tokyo 135-8601 Japan
^f National Institute of Health Sciences, 1-18-1 Ameyoko, Bunkyo-ku, 113-8531 Tokyo, Japan
^g Kao Corporation, Consumer Relations & Government Affairs 2-1-5, Mukai, Saitama-Ku, Tokyo 131-8501 Japan
^h Procter and Gamble Consumer Company NV, Simonsaan 100, B-1053 Brussels-Belem, Belgium
ⁱ Consumer Products (CP) Division, Global Toxicology and Cosmetology, Av. Europa 161, 50545 Sobral, Germany
^j US Food and Drug Administration (US FDA), Office of Cosmetics and Colors (OCC), Center for Food Safety and Applied Nutrition (CFSAN), 3801 Campus Drive, College Park, MD 20740, USA
^k Cosmetics Alliance Canada, 420 Brimley Road East Suite 302, Mississauga, ON L4Z 2L5, Canada
^l European Health Regulatory Agency (EHRA), Conférence de Pratiques de Hygiène, Pharmacie, Cosmétiques e Services, 104 Triche-S, lot 200, Arco Espagnol 17 - CSP 71200-010, Brazil
^m European Commission, Joint Research Centre (JRC), Directorate for Health, Consumer and Reference Materials, Chemical Safety and Alternative Methods Unit, Via E. Fermi 2749, 21027 Segrate, VA, Italy
ⁿ Cosmetics Europe, Avenue Hippocrate 60, 1160 Auderghem, Belgium
^o Health Canada (HC), Consumer Product Safety Directorate, Health Environment and Consumer Safety Branch, 200 Laurier Ave. W., Ottawa, ON K1A 0K9, Canada
^p Independent Cosmetic Manufacturers and Distributors (ICMAD), 21002 Field Parkway, Suite 2015, Deer Park, IL 60015, USA

MAXIMISING USE OF EXISTING INFORMATION AND NON-ANIMAL APPROACHES





- All available safety data (of suitable quality, appropriate dates)
 - public domain, historical in-house data, supplier data etc.
 - chemistry data, *in vitro* data, clinical data, epidemiological data, animal toxicology data, etc.
- Exposure-based waiving approaches
- History of safe use
- Read across
- Use of existing OECD *in vitro* approaches
- Next Generation Risk Assessment: Use of NAM (ICCR Principles)


ONE EXAMPLE NGRA WORKFLOW – THE NAMS USED




“THE ASSESSMENT IS EXPOSURE LED” - PBK



- Predicting systemic exposure
- Enabling us to select and test relevant doses
- Increased role for clinical work to confirm systemic exposure levels




EXPOSURE IN NEXT GENERATION RISK ASSESSMENT




“USING A TIERED AND ITERATIVE APPROACH”




New approach methodologies (NAMs)



PBK models



BioSpyder
cyprotex



eurofins SafetyScreen44™ Panel
Creep


Gene	Log2	Log2	Log2	Log2	Log2	Log2	Log2
ADAMTS	1.2	1.5	1.8	2.1	2.4	2.7	3.0
ADAM	1.1	1.4	1.7	2.0	2.3	2.6	2.9
ADAM10	1.0	1.3	1.6	1.9	2.2	2.5	2.8
ADAM17	0.9	1.2	1.5	1.8	2.1	2.4	2.7
ADAM19	0.8	1.1	1.4	1.7	2.0	2.3	2.6
ADAM20	0.7	1.0	1.3	1.6	1.9	2.2	2.5
ADAM21	0.6	0.9	1.2	1.5	1.8	2.1	2.4
ADAM22	0.5	0.8	1.1	1.4	1.7	2.0	2.3
ADAM23	0.4	0.7	1.0	1.3	1.6	1.9	2.2
ADAM24	0.3	0.6	0.9	1.2	1.5	1.8	2.1
ADAM25	0.2	0.5	0.8	1.1	1.4	1.7	2.0
ADAM26	0.1	0.4	0.7	1.0	1.3	1.6	1.9
ADAM27	0.0	0.3	0.6	0.9	1.2	1.5	1.8
ADAM28	-0.1	0.2	0.5	0.8	1.1	1.4	1.7
ADAM29	-0.2	0.1	0.4	0.7	1.0	1.3	1.6
ADAM30	-0.3	0.0	0.3	0.6	0.9	1.2	1.5
ADAM31	-0.4	-0.1	0.2	0.5	0.8	1.1	1.4
ADAM32	-0.5	-0.2	0.1	0.4	0.7	1.0	1.3
ADAM33	-0.6	-0.3	0.0	0.3	0.6	0.9	1.2
ADAM34	-0.7	-0.4	-0.1	0.2	0.5	0.8	1.1
ADAM35	-0.8	-0.5	-0.2	0.1	0.4	0.7	1.0
ADAM36	-0.9	-0.6	-0.3	0.0	0.3	0.6	0.9
ADAM37	-1.0	-0.7	-0.4	-0.1	0.2	0.5	0.8
ADAM38	-1.1	-0.8	-0.5	-0.2	0.1	0.4	0.7
ADAM39	-1.2	-0.9	-0.6	-0.3	0.0	0.3	0.6
ADAM40	-1.3	-1.0	-0.7	-0.4	-0.1	0.2	0.5
ADAM41	-1.4	-1.1	-0.8	-0.5	-0.2	0.1	0.4
ADAM42	-1.5	-1.2	-0.9	-0.6	-0.3	0.0	0.3
ADAM43	-1.6	-1.3	-1.0	-0.7	-0.4	-0.1	0.2
ADAM44	-1.7	-1.4	-1.1	-0.8	-0.5	-0.2	0.1
ADAM45	-1.8	-1.5	-1.2	-0.9	-0.6	-0.3	0.0
ADAM46	-1.9	-1.6	-1.3	-1.0	-0.7	-0.4	-0.1
ADAM47	-2.0	-1.7	-1.4	-1.1	-0.8	-0.5	-0.2
ADAM48	-2.1	-1.8	-1.5	-1.2	-0.9	-0.6	-0.3
ADAM49	-2.2	-1.9	-1.6	-1.3	-1.0	-0.7	-0.4
ADAM50	-2.3	-2.0	-1.7	-1.4	-1.1	-0.8	-0.5
ADAM51	-2.4	-2.1	-1.8	-1.5	-1.2	-0.9	-0.6
ADAM52	-2.5	-2.2	-1.9	-1.6	-1.3	-1.0	-0.7
ADAM53	-2.6	-2.3	-2.0	-1.7	-1.4	-1.1	-0.8
ADAM54	-2.7	-2.4	-2.1	-1.8	-1.5	-1.2	-0.9
ADAM55	-2.8	-2.5	-2.2	-1.9	-1.6	-1.3	-1.0
ADAM56	-2.9	-2.6	-2.3	-2.0	-1.7	-1.4	-1.1
ADAM57	-3.0	-2.7	-2.4	-2.1	-1.8	-1.5	-1.2
ADAM58	-3.1	-2.8	-2.5	-2.2	-1.9	-1.6	-1.3
ADAM59	-3.2	-2.9	-2.6	-2.3	-2.0	-1.7	-1.4
ADAM60	-3.3	-3.0	-2.7	-2.4	-2.1	-1.8	-1.5
ADAM61	-3.4	-3.1	-2.8	-2.5	-2.2	-1.9	-1.6
ADAM62	-3.5	-3.2	-2.9	-2.6	-2.3	-2.0	-1.7
ADAM63	-3.6	-3.3	-3.0	-2.7	-2.4	-2.1	-1.8
ADAM64	-3.7	-3.4	-3.1	-2.8	-2.5	-2.2	-1.9
ADAM65	-3.8	-3.5	-3.2	-2.9	-2.6	-2.3	-2.0
ADAM66	-3.9	-3.6	-3.3	-3.0	-2.7	-2.4	-2.1
ADAM67	-4.0	-3.7	-3.4	-3.1	-2.8	-2.5	-2.2
ADAM68	-4.1	-3.8	-3.5	-3.2	-2.9	-2.6	-2.3
ADAM69	-4.2	-3.9	-3.6	-3.3	-3.0	-2.7	-2.4
ADAM70	-4.3	-4.0	-3.7	-3.4	-3.1	-2.8	-2.5
ADAM71	-4.4	-4.1	-3.8	-3.5	-3.2	-2.9	-2.6
ADAM72	-4.5	-4.2	-3.9	-3.6	-3.3	-3.0	-2.7
ADAM73	-4.6	-4.3	-4.0	-3.7	-3.4	-3.1	-2.8
ADAM74	-4.7	-4.4	-4.1	-3.8	-3.5	-3.2	-2.9
ADAM75	-4.8	-4.5	-4.2	-3.9	-3.6	-3.3	-3.0
ADAM76	-4.9	-4.6	-4.3	-4.0	-3.7	-3.4	-3.1
ADAM77	-5.0	-4.7	-4.4	-4.1	-3.8	-3.5	-3.2
ADAM78	-5.1	-4.8	-4.5	-4.2	-3.9	-3.6	-3.3
ADAM79	-5.2	-4.9	-4.6	-4.3	-4.0	-3.7	-3.4
ADAM80	-5.3	-5.0	-4.7	-4.4	-4.1	-3.8	-3.5
ADAM81	-5.4	-5.1	-4.8	-4.5	-4.2	-3.9	-3.6
ADAM82	-5.5	-5.2	-4.9	-4.6	-4.3	-4.0	-3.7
ADAM83	-5.6	-5.3	-5.0	-4.7	-4.4	-4.1	-3.8
ADAM84	-5.7	-5.4	-5.1	-4.8	-4.5	-4.2	-3.9
ADAM85	-5.8	-5.5	-5.2	-4.9	-4.6	-4.3	-4.0
ADAM86	-5.9	-5.6	-5.3	-5.0	-4.7	-4.4	-4.1
ADAM87	-6.0	-5.7	-5.4	-5.1	-4.8	-4.5	-4.2
ADAM88	-6.1	-5.8	-5.5	-5.2	-4.9	-4.6	-4.3
ADAM89	-6.2	-5.9	-5.6	-5.3	-5.0	-4.7	-4.4
ADAM90	-6.3	-6.0	-5.7	-5.4	-5.1	-4.8	-4.5
ADAM91	-6.4	-6.1	-5.8	-5.5	-5.2	-4.9	-4.6
ADAM92	-6.5	-6.2	-5.9	-5.6	-5.3	-5.0	-4.7
ADAM93	-6.6	-6.3	-6.0	-5.7	-5.4	-5.1	-4.8
ADAM94	-6.7	-6.4	-6.1	-5.8	-5.5	-5.2	-4.9
ADAM95	-6.8	-6.5	-6.2	-5.9	-5.6	-5.3	-5.0
ADAM96	-6.9	-6.6	-6.3	-6.0	-5.7	-5.4	-5.1
ADAM97	-7.0	-6.7	-6.4	-6.1	-5.8	-5.5	-5.2
ADAM98	-7.1	-6.8	-6.5	-6.2	-5.9	-5.6	-5.3
ADAM99	-7.2	-6.9	-6.6	-6.3	-6.0	-5.7	-5.4
ADAM100	-7.3	-7.0	-6.7	-6.4	-6.1	-5.8	-5.5

CELL STRESS PANEL

Range of biomarkers covering ~10 cell stress pathways:

- Mitochondrial Toxicity: MitoSOX, PGC-1α, MIF, ATF, Gα10s
- Oxidative Stress: GSH, ROS, SIRT1, Nrf2
- DNA damage: pTAX, p53
- Inflammation: TNF-α, ICAM-1, NF-κB p65, IL-1β, IL-8, MCP-1
- ER Stress: PERK, ATF4, CHOP, XBP1, BiP, ER Tracker
- Metal Stress: MTF-1, Metallothionein
- Osmotic Stress: NRG1, Heat Shock (HSP90), Hypoxia (HIF-1α)
- Cell Health: LDH, Phosphatidylcholine, Stearic acid, pHeads indicator, apoptosis (Caspase-3/7 & necrosis [IL-1β])

cyprotex



HYPOTHETICAL CASE STUDY

INCLUSION OF 0.1% COUMARIN IN
FACE CREAM TO BE MARKETED IN **EUROPE**



Safety assessment
required

FRAMEWORK FOR THE COUMARIN CASE STUDY

Tier 0


Identify use scenario, chemical of concern and collect existing information

1. Identify Use Scenario

2. Identify Molecular Structure

3. Collect Existing Data

4. Identify analogues, suitability assessment



Existing in vivo and human data excluded. Read across excluded.

Tier 1

Hypothesis formulation for *ab initio* approach

5. Systemic bioavailability (Parent vs Metabolite, target organs, internal concentration).

6. MoA hypothesis generation (WoE based on available tools – *in silico*, *in chemico* and *in vitro*)

Tier 2

Application of *ab initio* approach

7a. Targeted testing

7b. Biokinetic refinement (*in vivo* clearance, population, *in vitro* stability, partition)

8. Point of Departure (PoD), IVIVE, Margin of Safety (MoS), Uncertainty Estimation

9. Final risk assessment or summary on insufficient information approach

Uncertainty


Mechanistic Understanding

TIER 0: IDENTIFY USE SCENARIO AND DETERMINATION OF APPLIED DOSE

1. Identify Use Scenario



Product types	Face cream
Amount of product used per day (g/day) using 90th percentile	1.54
Frequency of use	2 times/day
Amount of product in contact with skin per occasion (mg)	770
Ingredient inclusion level	0.1%
Skin surface area (cm ²)	565
Leave on or rinse off	leave on
Exposure duration per occasion	12 hours
For rinse off product, retention factor of finished product on skin ^b	n.a.
Amount of ingredient in contact with skin per occasion (mg)	0.77
Local dermal exposure per occasion (µg/cm ²)	1.36
Systemic exposure per day (mg/kg)	0.02



Cramer class III


Exposure to face cream is above TTC (2.3 µg/kg)

Risk assessment progresses to NGRA

TIER 0: IDENTIFY/CHARACTERISE MOLECULAR STRUCTURE



2. Identify Molecular Structure



In silico
predictions




QSAR TOOLBOX

ToxTree

ToxTree

- **Cramer class: High (III)**
- **Protein binding profiler:**
 - Alert for Michael acceptor
 - Alert for acyl transfer
- **DNA binding profiler:**
 - Alert for Michael acceptor

OECD Toolbox: identified alert for SN2 mechanism after oxidation to epoxide



Atlas of MIEs*

- Alert for Cyclooxygenases (Alert COX 2 - Cinnamaldehyde-like) was identified

	OECD Toolbox					ToxTree				DEREK NEXUS					MIE Atlas*					
	Mutagenicity	Endocrine Activity	Chromosome Damage	Protein Binding	DNA Binding	Mutagenicity	Genotoxicity	Protein Binding	DNA Binding	Mutagenicity	Genotoxicity	Endocrine Activity	Chromosome Damage	Skin/Eye Irritation	MAO A 2a	MAO A 2b	COX 2	MAR (1,2,3)	PDE 3A 4	A1a ADR
Coumarin Primary Metabolites (n=7)	Y	-	-	Y	Y	-	Y	Y	Y	-	-	-	-	-	-	-	Y	-	-	-
Secondary Metabolites (n=13)	-	7	-	13	10	-	-	13	13	-	2	1	5	3	-	6	6	7	2	1
Tertiary Metabolites (n=3)	-	3	3	3	2	-	-	3	3	1	-	-	-	-	-	2	-	-	-	-

*Allen THE et al., 2018. Using 2D Structural Alerts to Define Chemical Categories for Molecular Initiating Events. Toxicol Sci. 2018 Sep 1;165(1):213-223

Note: predictions that were based on coumarin's animal data were excluded - predictions from DEREK and TIMES-SS were not taken into account.

TIER 0: COLLECTION OF EXISTING DATA

3. Collect Existing Data

- ToxCast data excluded (considered a 'new' chemical)
- A review of the literature was done to validate predicted metabolites
- Literature review was also used for genotoxicity (overall negative decision)

TIER 1: SYSTEMIC BIOAVAILABILITY OF COUMARIN USING PBK MODELLING

Tier 0

Identify use scenario, chemical of concern and collect existing information

Tier 1

Hypothesis formulation for PBK modelling approach

Tier 2

Application of PBK modelling approach

5. Systemic bioavailability (Parent vs Metabolite, target organs, internal concentration).

Key output parameters from uncertainty analysis:

Parameter	Face cream (applied 2x/day)
Plasma C _{max} total (μM)	0.0023
95th percentile C _{max} (μM)	0.0043

0.1% Face cream in Europe, from 70kg male





Figure. Physiologically-based kinetic modelling using GastroPlus® v9.5. Parameters were estimated mainly based on experimental data (Cl_{int}, f_{up}, b_{pr}, solubility, LogP). Skin penetration parameters were fitted against skin pen data.

GENOTOXICITY SCREENING TOOL



WHY ToxTracker® ?

- Performance of the assay currently exceeds that of the regulatory 2-test battery (Hendriks et al., 2011, 2016)
- Potential to provide Mechanistic Information e.g. Oxidative stress MoA.
- Potential to integrate as part of a battery of NGRA approaches to strengthen confidence in MoA prediction.




RESULTS FOR COUMARIN

1. ToxTracker assay

Standard ToxTracker assay +S9					
DNA damage		p53	Ox. stress		UPR
Bscl2	Rtkn	Btg2	Srxn1	Blvrb	Ddit3
Green		Orange	Red	Red	Green
Standard ToxTracker assay -S9					
DNA damage		p53	Ox. stress		UPR
Bscl2	Rtkn	Btg2	Srxn1	Blvrb	Ddit3
Green		Green	Red	Green	Orange

- Positive (>2-fold induction)
- Weak activation (1.5 to 2-fold induction)
- Negative (<1.5-fold induction)



→ suggestive of reactive coumarin metabolite(s) inducing DNA lesions secondary to oxidative stress, rather than directly interacting with DNA

2. Literature review

The ToxTracker outcome is also supported by in vitro testing data in the literature suggesting that coumarin is not a genotoxic agent of relevance to humans.

- Ames test: Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 and TA1538, with and without S9. Weak positive results in TA100 +S9, at high concentrations*
- Low clastogenic activity in Chinese hamster ovary cells (Felter, Vassallo, Carlton, & Daston, 2006), at concentrations that exceed current testing guidelines (OECD, 2016)
- No induction of unscheduled DNA synthesis in cultured precision-cut human liver slices (Beamand, Barton, Price, & Lake, 1998)

TIER 1: MOA HYPOTHESIS GENERATION- IN VITRO BIOACTIVITY TOOLS- BIOMAP® DIVERSITY PLUS® 8



Uncertainty

Tier 0

Identify use scenario, chemical of concern and collect existing information

Tier 1


Hypothesis formulation for *in vitro* approach

Tier 2

Application of *in vitro* approach

6. MoA hypothesis generation (WoE based on available tools – *in silico*, *in chemico* and *in vitro*)

No immunomodulatory effects at relevant concentrations. Data suggest that coumarin is not an anti-inflammatory compound



Cell System	Endothelial (IL1b+TNFa+IFNy)	Endothelial (IL4+Hist)	PBMC + Endothelial (TLR4)	PBMC + Endothelial (TCR)	Bronchial Epithelial (IL1b+TNFa+IFNy)	Coronary artery SMCs (IL1b+TNFa+IFNy)	Fibroblasts (IL1b+TNFa+IFNy+EGF+bFGF+PDGF-BB)	Keratinocyte s + Fibroblasts (IL1b+TNFa+IFNy+TGFb)
LOEL	18.5µM	500µM	>500µM	>500µM	167µM	167µM	56µM	500µM



Mechanistic Understanding

TIER 1: MOA HYPOTHESIS GENERATION- IN VITRO BIOACTIVITY TOOLS- CEREP



Uncertainty

Tier 0

Identify use scenario, chemical of concern and collect existing information

Tier 1

Hypothesis formulation for *in vitro* approach

Tier 2


Application of *in vitro* approach

Mechanistic Understanding


MoA hypothesis generation (WoE based on available tools – *in silico*, *in chemico* and *in vitro*)

CEREP “Safety Screen 44”:
(based on Bowes et al 2012).

SafetyScreen44™ Panel



All binding and enzymatic assay results were negative at 10 uM, including COX-receptor1 and COX-2. No /target-led pharmacological effect



Bowes et al 2012. Nature Reviews: Drug Discovery 11 909-922

TIER 1: MOA HYPOTHESIS GENERATION- IN VITRO BIOACTIVITY TOOLS- CELL STRESS



Tier 0

Identify use scenario, chemical of concern and collect existing information

Tier 1

Hypothesis formulation for an in vitro approach

Tier 2

Application of an in vitro approach

MoA hypothesis generation (WoE based on available tools – *in silico*, *in chemico* and *in vitro*)

- **A Bayesian statistical approach** was applied to the dataset to derive a PoD with explicit uncertainty quantification

~40 biomarkers, 3 timepoints, 8 concentrations

Stress pathways

Mitochondrial Toxicity
Oxidative Stress
DNA damage
Inflammation
ER Stress
Metal Stress
Osmotic Stress
Heat Shock
Hypoxia
Cell Health

Platform

Technology: High content imaging
Cell line: HepG2
Timepoints: 1, 6 & 24 hours

TIER 1: MOA HYPOTHESIS GENERATION- IN VITRO BIOACTIVITY TOOLS- CELL STRESS



6. MoA hypothesis generation
(WoE based on available tools – *in silico*, *in chemico* and *in vitro*)

Summary table with PoD for cell stress biomarkers:

Biomarker	Cell type	Stress pathway	PoD (µM)	Effect
ATP (6h)	HepG2	Cell health	794	down
ATP (24h)			617	down
Phospholipidosis (24h)			759	down
GSH (24h)	HepG2	Oxidative stress	851	up
IL-8 (24h)	HepG2	Inflammation	912	down
OCR (1h)	NHEK	Mitochondrial toxicity	62	down
OCR (6h)			468	
OCR (24h)			309	
Reserve capacity (1h)	NHEK	Mitochondrial toxicity	44	down
Reserve capacity (6h)			759	
Reserve capacity (24h)			794	

- Only **cellular ATP, GSH, IL-8 and phospholipidosis** showed a dose response in HepG2 cells

PoD for cell stress biomarkers 24h in HepG2 and NHEK:

BIOSPYDER- TEMPO-SEQ TECHNOLOGY

- High-throughput gene expression profiling
- Performed at BioSpyder with Cyprotex

Defining a safe operating exposure for systemic toxicity using a **NOTEL** (no observed transcriptional effect level)



[Lobenhofer EK, Cui X, Bennett L, Cable PL, Merrick BA, Churchill GA, et al. Exploration of low-dose estrogen effects: identification of No Observed Transcriptional Effect Level (NOTEL). Toxicol Pathol. 2004;32(4):482-92]

Cell lines (chosen to express a range of relevant receptors)

MCF-7 – human breast adenocarcinoma cell line

HepG2 – human liver carcinoma

HepaRG – terminally differentiated hepatic cells that retain many characteristics of primary human hepatocytes




NOTEL* is the derived concentration of a compound that does not elicit a **meaningful** change in gene expression (i.e. the threshold of the concentration that elicits minimal mechanistic activity).

TIER 2: APPLICATION OF AB INITIO APPROACH – POD AND MOS PLOT



Point of Departure (PoD), IVIVE, Margin of Safety (MoS), Uncertainty Estimation

Face cream 0.1%



Cmax expressed as a distribution:

- Red line= median (50th percentile)

PoDs and plasma Cmax (µM) are expressed as total concentration.

Uncertainty

Mechanistic Understanding

Tier 0

Identify use scenario, chemical of concern and collect existing information

Tier 1

Hypothesis formulation for ab initio approach

Tier 2

Application of ab initio approach

TIER 2: APPLICATION OF AB INITIO APPROACH – RISK ASSESSMENT

Final risk assessment or summary on information generated SO FAR

Face cream


MoS considering lowest POD (HTTr HepG2) = 7223

MoS considering highest POD (Cell stress panel NHEK) = 1330

$$\text{MoS} = \frac{\text{POD}}{\text{Exposure}}$$



Most conservative
Plasma C_{max}
95th percentile



ONGOING WORK TO STRENGTHEN NGRA



- Generation of experimental data to further understand the influence of liver and skin **metabolism** on the risk assessment decisions is ongoing
- **Skin penetration data** is being analysed and incorporated in the PBK model
- Data generated in **metabolically competent cell lines or with metabolic activation** to help reduce uncertainty on potential metabolite-driven effects
- Approaches to analysing and interpreting *in vitro* data and **defining points of departure**, particularly for NOTEL values being further developed

CONCLUSIONS



- ICCR principles help us get to an NGRA decision
 - This case study appears to be protective of human health for a cosmetic product
- Importance of understanding consumer exposure
 - Including the relevance of metabolism
- Constructed from *in silico* modelling approaches and *in vitro* solutions
 - Need to ensure quality/robustness of the non-standard work and to characterise uncertainty to allow informed decision-making

Press Release October 15, 2019

The Humane Society of the United States announces honorees for “To the Rescue!” New York 10th Anniversary Gala

Nov. 15 event to honor Unilever, Patrick McDonnell and the Alex & Elisabeth Lewyt Charitable Trust

NEW YORK—The Humane Society of the United States today announced that consumer goods company Unilever, MUTTS® cartoonist and children’s book author Patrick McDonnell and the Alex & Elisabeth Lewyt Charitable Trust will be honored at the 2019 “To the Rescue!” New York 10th Anniversary Gala to benefit and celebrate the organization’s animal rescue efforts.



HUMANE SOCIETY
INTERNATIONAL



Unilever’s commitment to ending animal testing is underpinned by the work of its Safety & Environmental Assurance Center, which has worked since the 1980s to develop and use alternatives to animal tests for assessing safety, e.g. computer-based modelling and cell-based ‘in vitro’ methods. As part of Unilever’s commitment to ending animal testing, they have a growing number of brands that ensure that neither finished products nor the ingredients they use are subject to animal testing by suppliers or by regulatory authorities and are certified as such by animal welfare groups. Unilever was the first of the “top 5” beauty brands to call for a global ban on cosmetic animal testing in partnership with Humane Society International and the HSUS, and is a founding member of the Animal-Free Safety Assessment Collaboration, which works to accelerate global adoption of modern, human-based approaches to safety assessment that will better protect consumers and hasten the replacement of animal testing.

WWW.TT21C.ORG

QUESTIONS?

THANKS TO ALL THE SEAC TEAM AND
OUR MANY EXTERNAL PARTNERS

